As December approaches, investors in Singular Genomics Systems might find themselves pondering whether it's time to reevaluate their stakes in this NASDAQ-listed company. With the stock's valuation market value sitting at $23M and an EPS estimate for the current year showing a loss of 34.8, there's a lot to consider. The health care equipment and supplies sector can be volatile, and Singular Genomics is no exception. The company's financials and market dynamics suggest a complex landscape, making it crucial for private investors to weigh their options carefully. Let's take a closer look at Singular Genomics Systems. Despite some challenges, we're optimistic about a potential recovery. Currently, the stock is priced at $23.00. Historically, it has shown a hype elasticity of 3.56, while competitors average around -0.15. We anticipate a price increase to $26.56 following the next press release. However, the stock's volatility is extremely high, making social media predictions less reliable. We expect a 15.48% price jump with the upcoming news, and the daily expected return is 2.87%. With a 90-day investment horizon, the next announcement is expected in about 8 days.
The successful prediction of Singular Genomics
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Singular Genomics Systems, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Singular Genomics based on Singular Genomics hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Singular Genomics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Singular Genomics's related companies.
Use Technical Analysis to project Singular expected Price
Singular Genomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Singular Genomics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Singular Genomics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Singular Genomics Gross Profit
Singular Genomics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Singular Genomics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Singular Genomics Gross Profit growth over the last 10 years. Please check Singular Genomics'
gross profit and other
fundamental indicators for more details.
Breaking down the case for Singular Genomics
The company reported the previous year's revenue of 2.91
M. Net Loss for the year was (94.82
M) with loss before overhead, payroll, taxes, and interest of (24
K).
Current Deferred Revenue Breakdown
Singular Genomics' Current Deferred Revenue is increasing over the years with slightly volatile fluctuation. Current Deferred Revenue is expected to dwindle to about 4.5
M. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At present, Singular Genomics' Current Deferred Revenue is projected to increase significantly based on the last few years of reporting.
| 2010 | 1.59 Million |
| 2021 | 4.58 Million |
| 2023 | 6.08 Million |
| 2024 | 4.49 Million |
Timing can be everything in investing, and as December approaches, private investors in Singular Genomics Systems might find it prudent to reassess their positions. With a Price to Book ratio of just 0.24X, the stock may appear undervalued, suggesting potential for future growth. However, the company's high probability of bankruptcy at 96% and negative earnings per share estimates for both the current and next year highlight significant financial challenges. The firm's robust current ratio of 22.98X indicates strong liquidity, yet with a market capitalization of only 55.68 million, the road ahead could be bumpy. Investors should weigh these factors carefully, considering both the risks and opportunities before making any moves.
Our take on today Singular Genomics surge
Singular Genomics Systems has recently seen a significant uptick in its stock price volatility, with a standard deviation surpassing 17.47. This indicates that the market is reacting strongly to recent company news or developments. While such fluctuations can offer traders opportunities to profit from short-term price changes, they also highlight the need for careful analysis and risk management. Investors should stay informed about the factors driving this volatility to make informed decisions about their holdings in Singular Genomics.
The stock's above-average volatility suggests that understanding market trends can help investors better time their trades. During bear markets, increased volatility can impact Singular Genomics' stock price, prompting investors to adjust their portfolios by diversifying as prices decline.As we look towards December, Singular Genomics Systems presents an intriguing opportunity for investors willing to navigate its volatile landscape. With an analyst overall consensus of "Buy" and a possible upside price of
45.13, there's potential for significant gains. However, it's crucial to weigh this against the fiscal challenges, such as the EPS estimate for next year at -31.72, which indicates ongoing financial hurdles. Investors should carefully consider their risk tolerance and investment strategy before diving in, as the stock's journey could be as unpredictable as it is promising..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Singular Genomics Systems. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com